This report provides an overview of selected epidemiological characteristics of measles and rubella in the WHO European Region. It is primarily based on epidemiological data submitted to the centralized information system for infectious diseases. ${ }^{1}$ The analyses of these diseases are performed on cases with disease onset dates during the first quarter of 2014. Where these dates were unavailable, cases with the date of notification reported during this period were included.

The reader is referred to WHO EpiData no. 03/2014, which includes tabulated surveillance data by country corresponding to the period of reporting (January to March 2014). ${ }^{2}$ This issue reports specifically on measles in the Czech Republic, Ireland, Latvia, Poland, the Russian Federation, Spain and the former Yugoslav Republic of Macedonia, and on rubella in the Russian Federation.

## Measles from January to March 2014

Incidence - notifications and laboratory data
For the first quarter of 2014, 6335 measles cases were reported in 28 countries of the WHO European Region among 49 ( $92 \%$ ) countries that submitted measles data (including zero reporting). Four countries, namely Bosnia and Herzegovina, Monaco, San Marino, and Turkmenistan did not submit reports.

Of the total, $83 \%$ of cases ( $\mathrm{n}=5228$ ) were reported by four countries: Russian Federation ( $\mathrm{n}=2590$; 41\%), Ukraine (977; 15\%), Georgia (930; 15\%) and Italy (791; $12 \%)$. With 1390 cases of measles, the 28 Member States constituting the European Union reported 25\% of all cases in the Region. The highest incidence per million population for the first quarter of 2014 was reported in Georgia (218.7) followed by Ukraine (22.2) and the former Yugoslav Republic of Macedonia (22.0).

Of the total, 3933 (62\%) cases were laboratoryconfirmed and 430 (7\%) were epidemiologically linked cases. The remaining 1972 (31\%) were classified as clinically compatible cases. During the first quarter of 2014, 265 clinical specimens were sequenced (reported as of 12 June 2014). The sequence data were entered in the Measles Nucleotide Surveillance

Fig. 1. Age distribution of measles cases in the WHO European Region, first quarter of 2014 ( $n=6333$ )

N.B. Discarded cases are not included
database (MeaNS) by national or reference laboratories of the WHO European Region. The genotypes identified in the Region included B3 ( $n=140$ ), D8 (118) and H1 (5).

## Age distribution

The age group was known in 6333 cases (99.97\%). Forty-three percent of cases ( $n=2733$ ) were 20 years and older (Fig. 1). Fig. 2 overleaf shows the age distribution of measles cases in the four countries that reported $83 \%$ of cases in the Region.

## Vaccination status

Vaccination status was known in 4955 cases (78\%). Of the 3362 unvaccinated cases (68\%), all had data on age: 591 cases (18\%) were <1 year old, 788 cases (23\%) were 1-4 years old, 408 cases (12\%) were 5-9 years old, 541 cases (15\%) were 10-19 years old and 1061 cases (32\%) were $\geq 20$ years old. The remaining 1593 cases (32\%) were reportedly vaccinated with at least one measles-containing vaccine dose. The age group $\geq 20$ years old had the largest proportion of cases (40\%; $\mathrm{n}=1082$ ) without information on vaccination status.

## Hospitalization

Data on hospitalization status was available for 66\% ( $n=4199$ ) of all reported measles cases. There were 3308 reported hospitalized cases in connection with measles, amounting to $79 \%$ of all cases with known hospitalization status.

[^0]Fig. 2. Age distribution of measles cases in the four countries that reported most (83\%) cases in the WHO European Region, first quarter of 2014 ( $n=5288$ )


Imported cases
Importation status was known in 34\% ( $n=2160$ ) of cases. Of these, 115 were reported as imported cases, amounting to $5.3 \%$ of cases with a known importation status.

## Measles outbreak in the Czech Republic

An outbreak of measles is ongoing in the northwestern part of the Czech Republic. Between 26 January 2014, when the index case first developed symptoms, and 21 May 2014, 220 suspected measles cases were reported. Of these, 171 cases were laboratory-confirmed. The index case was a 47-year-old man with a history of travel to India during the incubation period. Initially, the infection spread to seven close contacts of the index case. However, the focus of the outbreak later shifted to involve health care workers working in the

infectious disease, dermatology and emergency departments of the hospital in the region of Ústí nad Labem where he was admitted. By 30 April 2014, 68 health care workers were laboratory-confirmed for measles: 41 nurses, 11 medical doctors and 16 other hospital workers.

Measles virus genotype B3 was identified. Most cases ( $70 \%$; $n=120$ ) were 30 years and older (Fig. 3). Vaccination status was known in 141 (82\%) out of the 171 cases: 32 cases (19\%) were unvaccinated and 109 cases (77\%) reported having received at least one measles-containing vaccine dose.

To date, no measles-related deaths have been reported since the start of the outbreak. However, 23 cases were hospitalised and three cases developed acute pneumonia as a complication of measles.

Fig. 3. Age distribution of laboratory confirmed measles cases in the Czech Republic, 26 January-21 May 2014 ( $\mathrm{n}=171$ )


## Outbreak control measures

The local public health authorities issued a press release on the outbreak and alerted hospitals and primary health care providers in the region. They are also collaborating with general practitioners to actively trace contacts and recommend vaccination to unvaccinated or incompletely vaccinated individuals. A vaccination campaign targeting health care workers born in the years 1970-1980 is ongoing. By 21 May 2014, 200 health care workers received the combined measles, mumps and rubella (MMR) vaccine. The Ministry of Health is providing the necessary financial support to ensure sufficient vaccine supply.

## Measles in Ireland

An outbreak of measles has occurred in Ireland. The first identified case of the outbreak developed a rash on 21 March 2014, and by 25 April 2014, 14 additional cases of measles were reported. The outbreak was announced on 27 March 2014, when two cases linked to National University of Ireland in Galway were reported to the local public health authorities. Further cases were reported among other university and thirdlevel college students in the region, and close contacts of students in the city of Galway and the western counties of Galway, Mayo and Kerry. There is as yet no known history of travel among the first cases to suggest importation of the measles virus from abroad.

Of the total 15 cases reported with measles, 10 cases were laboratory-confirmed. Measles virus genotype D8 (Frankfurt Main lineage) was identified in clinical
specimen of four cases. The reported cases were distributed by age group as follows: eight cases were 14-19 years old and seven cases were 20 years and older. Vaccination status was known in 12 out of the 15 cases: eight cases were unvaccinated, one case had received one measles-containing vaccine dose and three cases reported having received two vaccine doses. To date, no measles-related deaths have been reported since the start of the outbreak.

## Outbreak control measures

The local public health authorities issued a press release on the outbreak and communicated alerts to students and academic staff in the universities and third level colleges in Galway. Alerts were also distributed to hospitals and primary health care providers.

The local public health authorities are advising students to check their vaccination status against measles and, if necessary, be vaccinated at student health services or at their own general practitioner. Students who are feeling unwell are also being asked to seek medical advice by phone and to stay at home during the period of illness to prevent transmission to others.

At a national level, alerts and information were disseminated to all departments of public health in the country. The Health Protection Surveillance Centre (HPSC) is providing regular updates of the measles situation on its website, while also urging all university students in the country to review their vaccination status and be vaccinated accordingly.

## Measles outbreak in Latvia

An outbreak of measles has occurred in Latvia. This follows a decade, since 2004, in which a total of 16 cases were reported. The first case for 2014 was a $24-$ year-old woman living in the eastern part of the country. She developed a rash on 12 March 2014. The case was notified on 18 March 2014. This case gave rise to three secondary cases: two health care workers (a doctor and a nurse assistant) and one family member. So far, no history of travel abroad or contact with someone returning from abroad has been established among the first cases.

By 13 May 2014, 31 laboratory-confirmed cases were reported mostly in the capital Riga but also in the regions of Pieriga, Latgales, Vidzemes and Zemgales, although not all cases could be epidemiologically
linked to the same cluster. Measles virus genotype B3 (Harare lineage) was identified in clinical specimens of eight laboratory-confirmed cases.

Most cases (58\%; $n=18$ ) were 30 years and older (Fig. 4). Vaccination status was known in 16 out of the 31 cases: 11 cases were unvaccinated, two cases had received one measles-containing vaccine dose and three cases reported having received two vaccine doses. Among the unvaccinated cases there were five infants <12 months of age. To date, no measles-related deaths have been reported since the start of the outbreak. However, 22 cases were hospitalized.

Nosocomial transmission occurred in three hospitals and affected 13 health care workers, including three medical doctors, four nurses, three laboratory specialists and four hospital auxiliary staff (administration, IT specialist). Of these, five cases were unvaccinated, one case had received one measlescontaining vaccine dose, two cases reported having received two vaccine doses and in five cases vaccination status was unknown. No secondary cases of measles were identified among hospitalized patients.

Two adults, who acquired the infection in Latvia, travelled on different international flights for short business trips during the incubation and/or prodrome period. The cases were reported with measles upon their return to Latvia. No secondary cases were reported among passengers or aircrew of the aircrafts nor among the cases' contacts abroad.

## Outbreak control measures

In response to the outbreak, the Centre for Disease Prevention and Control of Latvia (CDPC) disseminated recommendations to the general public through the media. The general public and health care workers are invited to check immunization status through medical records and get vaccinated, if necessary. These recommendations and regular updates on the outbreak are made available on CDPC's website.

Recommendations emphasizing the appropriate prevention and control measures were also distributed by post to health care professionals (general practitioners, paediatricians and hospital authorities). General practitioners were requested to monitor cases' contacts by asking them to report for a period of 17 days after contact with the patient any signs and symptoms suggestive of the disease by phone. In this way patients receive immediate medical attention and

Fig. 4. Age distribution of laboratory confirmed measles cases in Latvia, 12 March -13 May 2014 ( $n=31$ )

avoid transmitting the infection at health care facilities and public places.

Each suspected and confirmed case of measles is being carefully investigated by regional epidemiologists of CDPC and response measures are being organized in collaboration with general practitioners: identification and reporting of contacts, organization of their immunization with MMR vaccine in cases with no evidence of vaccination in medical records and monitoring of contacts for signs and symptoms of the disease.

In the case of the two travellers with measles, the other passengers and aircrew of the aircrafts on which they flew were traced. Lists of potentially exposed passengers and aircrew were sent to relevant national public health authorities of other countries using the selective exchange option of the international Early Warning and Response System.

## Measles outbreak in Poland

An outbreak of measles has occurred in the province of Wielkopolskie in Poland. Between 2 January 2014, when the first identified case of the outbreak developed a rash, and 7 May 2014, 62 cases of measles were reported. The first outbreak case was notified to the local public health authority in the province's capital Poznań on 13 January 2014. The last case had date of onset of rash on 22 April 2014.

The source of infection for the first cases could not be identified. The outbreak mostly (74\%; $n=46$ ) affected
members of the Roma community and the remaining cases were reported in the general population. Of the total 62 cases, 48 cases were laboratory-confirmed. In seven cases measles virus genotype D8 was identified. This measles virus variant widely circulated in the Russian Federation in 2013.

The median age was 14 years (range: nine months to 44 years). Almost a third of the cases were $10-19$ years of age (Fig. 5).

Vaccination status was known for 50 cases -48 were unvaccinated and included two infants below the recommended age for the first MMR vaccine dose. The other two cases were vaccinated with one dose of measles vaccine. Four cases occurred in a kindergarten. Seven cases experienced complications (three patients had pneumonia and four had diarrhoea). No measles-related deaths have been reported.

## Outbreak control measures

Outbreak control measures in the province's capital Poznań included a vaccination campaign targeting susceptible health care workers in the two hospitals where patients with measles were admitted. In addition, a meeting held on 15 April 2014 at the Wielkopolskie Province Governor's Office brought together representatives from the district sanitary station in Poznań, the province's legal office of national minorities and the Roma Union. The aim was to encourage Roma to be vaccinated and to urge symptomatic cases to avoid contact with other community members. By the end of April, the head of the Roma Union was provided with a list of six primary

Fig. 5. Age distribution of reported measles cases in Poland, 2 January-22 April 2014 ( $n=62$ )

health care units providing free vaccination to all Roma children.

The district sanitary station in Poznań collaborated with local media to disseminate information through local newspapers, radio and television on the prevention of infectious diseases with particular emphasis on vaccination against measles.

## Measles in the Russian Federation

The Russian Federation reported 2590 cases of measles for the first quarter of 2014 corresponding to an incidence of 18.2 per million inhabitants. As in 2011-2013, most cases (96\%) were reported from Moscow, the Southern Federal District and the North -Caucasus Federal District.

In localized outbreaks there were cases of measles among individuals who were unvaccinated primarily because of philosophical and religious reasons. During the first quarter of 2014, 212 members of a Baptist community were affected. Measles cases among Roma communities have also been reported.

Of the total reported cases, 2262 cases (87\%) were laboratory-confirmed, 318 cases (12\%) were epidemiologically linked and 10 cases (0.4\%) were classified as clinically compatible cases.

Fig. 2. on page 2 shows the age distribution of laboratory-confirmed measles cases in the Russian Federation in the first quarter of 2014. Most cases (49\%; $n=1268$ ) were reported in adults 20 years of age and older. Of the 269 measles cases in infants <1 year of age, 81 infants ( $30 \%$ ) were $<6$ months of age.

According to preliminary data, four cases acquired measles abroad. The remaining cases are believed to have acquired the infection in the country. Measles virus genotype strains were identified in 76 measles cases in 25 out of 83 territorial regions of the country. Most measles virus strains (72) belonged to the D8 genotype. The D4 genotype was isolated in three cases in St Petersburg, and genotype B3 in one case, reported in Khabarovsk. As in 2013, the D8 genotype strains were represented by two genetic measles virus lineages Villupuram and Frankfurt Main.

Vaccination status was known in 1978 (76\%) out of the 2590 cases: 1357 cases ( $69 \%$ ) were unvaccinated and 621 cases (31\%) reported having received at least
one measles-containing vaccine dose. Of the unvaccinated cases, 269 cases occurred in infants younger than the recommended 12 months of age for the first dose of MMR vaccine according to the national childhood immunization programme. Of the remaining 612 cases (24\%) with an unknown immunization status, 505 cases were 20 years of age and older.

To date, no measles-related deaths for the first quarter of 2014 have been reported. However, 2077 patients ( $80 \%$ ) were admitted to hospital for isolation purposes in line with current national public health practices.

## Outbreak control measures

The Federal Service for Supervision of Consumer Rights Protection and Human Well-Being (Rospotrebnadzor) within the Ministry of Social and Medical Development is undertaking "mop-up" supplementary immunization activities in high-risk areas and populations. The mop-up immunization launched in December 2013 is currently being implemented in Dagestan and Chechnya among adults 20-29 years of age who are unvaccinated or have unknown vaccination history. In these regions an additional vaccination campaign is planned among 15-17 year olds who are unvaccinated or have had only one dose of live measles vaccine.

Local epidemiologists of the Federal Service are actively involved with Roma leaders and religious leaders on vaccination issues, and the Service has been conducting regular press conferences to inform the media and the public. The current epidemiological situation with measles and the importance of vaccination as a preventive measure are regularly covered in the press.

## Measles outbreak in Spain

An outbreak of measles has occurred in Spain. The index case was an unvaccinated 37 -year-old man from the Philippines living in the city of Barcelona in the autonomous community of Catalonia. He had a history of travel to the Philippines during the incubation period and developed a rash on 3 January 2014. By 5 May 2014, 120 cases were reported with spread to the Catalan provinces of Girona (11 cases) and Lleida (1 case), the autonomous community of Valencia (1 case) and the Balearic islands (1 case).

Of the total 120 cases reported with measles, 113 cases were laboratory-confirmed. Measles virus genotype B3 (Harare lineage) was identified in clinical specimens of 29 cases. Most cases (50\%; n=60) were 30 years and older (Fig. 6). Vaccination status was known in 112 out of the 120 cases: 89 cases were unvaccinated, 11 cases had received one measlescontaining vaccine dose and 12 cases reported having received two vaccine doses. To date, no measlesrelated deaths have been reported since the start of the outbreak. However, 33 cases were admitted to hospital suffering from acute pneumonia.

Thirty cases (24\%) were health care workers including four medical doctors, 14 nurses and 12 hospital auxiliary staff (transport, administration). Of these, 22 cases were unvaccinated and in one case vaccination status was unknown. Moreover, eight cases resulted from nosocomial transmission.

## Outbreak control measures

In response to the outbreak, the regional and local public health authorities of the affected areas are coordinating efforts to investigate cases thoroughly and trace susceptible contacts to vaccinate them. Updated information on the outbreak is being disseminated through the websites of the regional health authorities in Catalonia to the epidemiological surveillance units and the public.

Since the beginning of the outbreak several ad hoc reports have been disseminated to stress the importance of vaccination to health care workers and travellers. MMR vaccination is recommended for

Fig. 6. Age distribution of measles cases in Spain, 3 January -5 May 2014 ( $\mathrm{n}=120$ )

travellers, especially those travelling to areas where measles is endemic or where measles outbreaks are ongoing. The regional public health authorities are ensuring adequate stock and proper distribution of vaccines to the health care centres.

Two press releases on the outbreak were issued in February and March 2014 and featured in local newspapers in Barcelona and Girona. Television and radio interviews with the head of the Public Health Administration and other public health experts were also broadcasted.

Measles outbreak in the former Yugoslav Republic of Macedonia

An outbreak of measles has been ongoing in the former Yugoslav Republic of Macedonia since 6 January 2014 when the first case was identified. By 18 May 2014, 115 cases of measles were reported, all among the general population. Most (111) cases occurred in the region of the capital city Skopje and four cases were reported in the municipalities of Bitola (2), Radovish (1) and Kumanovo (1).

Of the total 115 cases, 49 cases ( $43 \%$ ) were laboratoryconfirmed and 19 cases (17\%) were epidemiologically linked to a laboratory-confirmed case. The remaining 47 cases were classified as clinical cases. In seven cases, measles virus genotype D8 (Frankfurt Main lineage) was identified, all with identical sequences. The outbreak peaked during week 13 (24-30 March 2014) with 22 cases having had onset of rash during that week. The largest percentage of cases occurred among those aged 30 years and older ( $n=50$ ) (Fig. 7).

Fig. 7. Age distribution of measles cases in the former Yugoslav Republic of Macedonia, 6 January-18 May 2014 ( $\mathrm{n}=115$ )


Of the total 115 cases, 91 cases (79\%) were unvaccinated. These included 19 infants younger than 12 months of age when the first dose of MMR vaccine is recommended by the national childhood immunization programme. Of the remaining 24 cases (21\%), seven cases had received one measles vaccine dose, two cases had received two vaccine doses and in 15 cases vaccination status was unknown. For the cases vaccinated with two MMR vaccine doses, no clinical specimens were provided to confirm the diagnosis using laboratory tests.

To date, no measles-related deaths have been reported. However, 71 cases ( $62 \%$ ) were hospitalized. Complications were reported in 16 (14\%) cases: 15 patients suffered acute pneumonia and one case, a 15-month-old child, had diarrhoea. Most of the complications were registered in the age groups 1-4 years ( 6 cases) and 30-39 years ( 6 cases).

## Outbreak control measures

National, regional and local public health authorities have been collaborating with the media to alert the general public on the outbreak and increase awareness on the importance of being vaccinated with the MMR vaccine. Information leaflets on measles and the importance of vaccination against the disease have been distributed in Macedonian and Albanian.

The regional Centre of Public Health (CPH) of Skopje is investigating all suspected cases of measles and contact tracing for the identification of susceptible individuals. To date, the immunization status of 333 contacts has been checked. Among these, 91 unvaccinated persons and 98 other persons without any documentation on vaccination status were identified and recommended to be vaccinated. CPH teams have been visiting all immunization sites in the city to monitor the immunization coverage more closely and to follow up on performance of the routine immunization of children. The same activities in other municipalities outside Skopje are being carried out by the regional public health authorities of Bitola, Kumanovo and Shtip (for Radovish).

Rubella from January to March 2014
Incidence - notifications and laboratory data
For the first quarter of 2014, 2449 rubella cases were reported in nine countries of the WHO European

Region among 42 (79\%) countries submitting rubella data (including zero reporting). The cases were reported almost exclusively by Poland ( $n=2349 ; 96 \%$ ), which also had the highest incidence per million population (61).

Of the total, 35 (1.4\%) cases were laboratoryconfirmed. These cases were reported by the Russian Federation (23), Kazakhstan (6), Norway (2), Austria (1), Bulgaria (1), Georgia (1) and Sweden (1). During the first quarter of 2014, no rubella virus sequence was entered in the Rubella Nucleotide Surveillance database (RubeNS). ${ }^{4}$

## Age distribution

The age group was known in all 2449 cases, of which 549 cases ( $22 \%$ ) were $15-19$ years old and 629 cases ( $26 \%$ ) were $\geq 20$ years old (Fig. 8).

## Vaccination status

Vaccination status was known in 2042 cases (65\%). All 1071 (52\%) unvaccinated cases had data on age: 62 cases ( $6 \%$ ) were $<1$ year old, 59 cases ( $6 \%$ ) were 1 -4 years old, 58 cases (5\%) were 5-9 years, 472 cases (44\%) were $10-19$ years old and 420 cases (39\%) were $\geq 20$ years old. The remaining 971 cases ( $48 \%$ ) were reportedly vaccinated with at least one rubellacontaining vaccine dose. These were reported mostly by Poland ( $96 \%$; $n=933$ ).

## Imported cases

Importation status was known in 2\% ( $n=48$ ) of rubella cases. Of these, 5 were reported as imported cases,

Fig. 8. Age distribution of rubella cases in the WHO European Region, first quarter of 2014 ( $n=2449$ )

amounting to $10.4 \%$ of cases with a known importation status.

## Rubella in the Russian Federation

For the first quarter of 2014, there were 23 laboratory-confirmed cases of rubella reported in four out of 83 territorial regions of the Russian Federation. Most cases ( $65 \%$, $n=15$ ) were adults 20 years of age and older: 12 cases were between 25-29 years of age and three cases were between 45-49 years of age. For the remaining eight cases, six cases were 15-19 years old and two cases were 1-9 years old. There is as yet no evidence to indicate rubella virus importation from abroad and therefore it is believed that the infection was acquired within the country. 14 patients (61\%) were hospitalized in line with current national public health practices. Vaccination status was known in 10 cases (43\%): two were unvaccinated and eight were reported to have received at least one dose of rubella vaccine.

The local health authorities are intensifying the investigation of vaccinated cases. A rubella seroprevalence study will include adults to determine their level of susceptibility to rubella.

## Comments

## Measles and rubella

The number of reported measles cases in the European Region for the first quarter of 2014 is $19 \%$ lower than that reported for the corresponding period in 2013 ( $n=7858$ ). However, several countries experienced new outbreaks in 2014 while in others measles transmission intensified. Measles affected individuals of all age groups. Overall, during the first quarter of 2014, over $40 \%$ of cases were adults aged 20 years and older. The age distribution of cases varied in the different countries reflecting the timing of the implementation of measles vaccination programmes, strategies used and coverage achieved.

Most measles outbreaks affected the general population, but outbreaks in particular groups continue to be reported. So far in 2014, the measles outbreak in Poland has affected mostly unvaccinated Roma.

The outbreaks reported from the Czech Republic, Latvia and Spain demonstrate the continued presence of susceptible health care workers.

Nosocomial transmission is of particular concern because of the potential spread to the general population and the risk of serious complications in hospitalized infants and adults who may already be debilitated from other medical conditions.

Rubella continues to be reported in much fewer countries than measles. Although still too high, the number of reported cases in the European Region for the first quarter of 2014 is $77 \%$ lower than that reported for the corresponding period in 2013 ( $n=10543$ ). This is primarily because the number of reported rubella cases reported in Poland dropped from 10441 in 2013 to 2349 for the same period in 2014. Nevertheless, the lack of a response measure to control the outbreak and laboratory confirmation of reported cases in Poland remain of concern in relation to the 2015 goal for eliminating the disease.

The relatively large proportion of measles cases in children $<5$ years of age ( $28 \%$ ) and adults $>20$ years of age (43\%) in the Region is important to note as the risk of serious measles-related complications (such as acute pneumonia and acute encephalitis) is increased in these age groups. Overall, $10 \%$ of cases occurred in infants $<1$ year of age in whom measles is particularly dangerous as infection may lead to the rare but invariably fatal complication of subacute sclerosing panencephalitis. Infants' protection against measles depends on their maternal antibodies. However, as these wane, infants become increasingly dependent on herd immunity until they reach the recommended age (usually 12-15 months) to receive their first MMR vaccine dose. Maintaining high vaccination coverage and closing immunity gaps in the adult population will therefore also protect vulnerable infants.

Susceptible individuals intending to visit areas where measles and rubella transmission is ongoing should receive the MMR vaccine. When importation of these diseases occurs, rapid and appropriate investigation
and response measures need to be taken to reduce the risk of virus spread. A high index of suspicion of these diseases is required also in adults who present with a rash after travelling to areas where measles and rubella transmission is ongoing.

Every country should ensure that their immunization programmes reach and maintain high MMR vaccination coverage, whilst also improving their capacity to identify susceptible individuals and to close immunity gaps in the population.

All the necessary precautions should be taken to prevent measles transmission in health care settings by implementing effective infection control practices. In addition, health authorities should strongly consider vaccination of susceptible health care workers against measles and rubella, and other vaccine-preventable (such as pertussis and chickenpox), as a standard of care in the context of occupational health but also patient safety.

The role of the media and internet are powerful sources of information on health, and as such instrumental in informing the public on the benefits of vaccination and vaccine safety. They have also been used to provide updates on the state of measles outbreaks and remind the public as well as health care workers of the importance of being vaccinated.

The current epidemiological situation of measles and rubella in the Region during the first quarter of 2014 remains of concern. Although intensified efforts are being taken by many countries, commitment to eliminate these diseases needs to be enhanced and continual throughout the Region.

Date of publication: June 2014
Suggested citation: WHO EpiBrief, 2014, 2:1-9
© World Health Organization, 2014.
All rights reserved. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

A monthly summary of the epidemiological data on selected vaccine-preventable diseases in the European Region

Monthly summary table 1: Reported measles cases for the 12-month period Apr 2013 - Mar 2014 (data as of 29 April 2014)

| Country | Total Population ${ }^{1}$ | Incidence Rate per 1 million population Apr 13-Mar 14 | Total measles cases Apr 13Mar 14 | 2013-2014 (Year and month of rash onset) |  |  |  |  |  |  |  |  |  |  |  | Month of last report 2014 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Jan | Feb | Mar |  |
| Albania | 3238959 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Mar |
| Andorra | 67704 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | Feb |
| Armenia | 3116607 | 3.5 | 11 | 0 | 5 | 3 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Mar |
| Austria | 8432566 | 12.7 | 107 | 13 | 10 | 4 | 2 | 4 | 7 | 8 | 2 | 9 | 32 | 11 | 5 | Mar |
| Azerbaijan | 9523077 | 11.9 | 113 | 23 | 47 | 28 | 4 | 0 | 0 | 0 | 0 | 0 | 2 | 4 | 5 | Mar |
| Belarus | 9503385 | 1.5 | 14 | 1 | 0 | 2 | 1 | 1 | 0 | 3 | 3 | 3 | 0 | 0 | 0 | Mar |
| Belgium | 10801368 | 3.8 | 41 | 7 | 11 | 5 | 2 | 2 | 0 | 0 | 0 | 0 | 4 | 7 | 3 | Mar |
| Bosnia and Herzegovina | 3736568 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | No Report |
| Bulgaria | 7350986 | 1.9 | 14 | 0 | 6 | 8 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | Mar |
| Croatia | 4378643 | 0.5 | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | Mar |
| Cyprus | 1140285 | 3.5 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | Mar |
| Czech Republic | 10573470 | 6.9 | 73 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 44 | 23 | Mar |
| Denmark | 5607702 | 3.4 | 19 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 8 | Mar |
| Estonia | 1338490 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Mar |
| Finland | 5413974 | 0.7 | 4 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | Mar |
| France | 63742992 | 4.8 | 307 | 46 | 37 | 34 | 25 | 13 | 13 | 15 | 11 | 7 | 41 | 38 | 27 | Mar |
| Georgia | 4278919 | 1904.0 | 8147 | 1987 | 2446 | 1522 | 662 | 156 | 142 | 65 | 93 | 144 | 200 | 244 | 486 | Mar |
| Germany | 81788064 | 21.7 | 1776 | 177 | 533 | 355 | 258 | 142 | 108 | 60 | 39 | 23 | 16 | 33 | 32 | Mar |
| Greece | 11441413 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | Mar |
| Hungary | 9932038 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Mar |
| Iceland | 331528 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | 0 | 0 | - | Feb |
| Ireland | 4628791 | 16.0 | 74 | 5 | 10 | 7 | 2 | 4 | 7 | 12 | 4 | 1 | 3 | 8 | 11 | Mar |
| Israel | 7801150 | 2.2 | 17 | 12 | 0 | 1 | 0 | 1 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | Mar |
| Italy | 60961372 | 41.6 | 2536 | 212 | 356 | 383 | 200 | 74 | 42 | 37 | 178 | 263 | 315 | 205 | 271 | Mar |
| Kazakhstan | 16552683 | 6.6 | 110 | 0 | 2 | 9 | 4 | 5 | 2 | 12 | 20 | 19 | 12 | 25 | - | Feb |
| Kyrgyzstan | 5515034 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | 0 | 0 | 0 | Mar |
| Latvia | 2225816 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Mar |
| Lithuania | 3280161 | 11.3 | 37 | 5 | 25 | 5 | 0 | - | 0 | 0 | 0 | - | 0 | 0 | 2 | Mar |
| Luxembourg | 528286 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | No Report** |
| Malta | 420515 | 4.8 | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Mar |
| Monaco | 38659 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | No Report |
| Montenegro | 633200 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | Feb |
| Netherlands | 16749476 | 159.0 | 2663 | 5 | 18 | 295 | 700 | 407 | 444 | 473 | 177 | 106 | 38 | 0 | - | Feb |
| Norway | 4984475 | 1.4 | 7 | 0 | 1 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Mar |
| Poland | 38317684 | 3.2 | 122 | 11 | 15 | 20 | 5 | 0 | 1 | 1 | 2 | 2 | 28 | 24 | 13 | Mar |
| Portugal | 10694259 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Mar |
| Republic of Moldova | 3504756 | 7.7 | 27 | 0 | 1 | 10 | 5 | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Mar |
| Romania | 21343840 | 26.1 | 557 | 146 | 80 | 127 | 83 | 27 | 11 | 24 | 21 | 12 | 26 | 0 | 0 | Mar |
| Russian Federation | 142512768 | 33.8 | 4820 | 105 | 222 | 208 | 77 | 79 | 124 | 220 | 490 | 705 | 1056 | 887 | 647 | Mar |
| San Marino | 29625 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | No Report |
| Serbia | 9827512 | 0.1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Mar |
| Slovakia | 5486391 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Mar |
| Slovenia | 2043666 | 0.5 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Mar |
| Spain | 46949824 | 2.3 | 107 | 15 | 15 | 18 | 31 | 8 | 4 | 3 | 0 | 0 | 8 | 3 | 2 | Mar |
| Sweden | 9532211 | 4.0 | 38 | 0 | 11 | 15 | 3 | 0 | 0 | 0 | 0 | 0 | 5 | 4 | 0 | Mar |
| Switzerland | 7753209 | 23.5 | 182 | 6 | 9 | 47 | 55 | 35 | 9 | 2 | 3 | 3 | 6 | 4 | 3 | Mar |
| Tajikistan | 7190283 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Mar |
| The former Yugoslav Republic of Macedonia | 2068552 | 23.2 | 48 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 6 | 6 | 34 | Mar |
| Turkey | 75356656 | 60.8 | 4579 | 1313 | 1267 | 859 | 378 | 89 | 52 | 73 | 102 | 106 | 80 | 154 | 106 | Mar |
| Turkmenistan | 5232704 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | No Report |
| Ukraine | 44722880 | 72.4 | 3239 | 252 | 266 | 257 | 138 | 47 | 149 | 401 | 535 | 217 | 394 | 261 | 322 | Mar |
| United Kingdom | 63162324 | 17.2 | 1084 | 478 | 233 | 124 | 81 | 22 | 15 | 28 | 13 | 4 | 39 | 27 | 20 | Mar |
| Uzbekistan | 28429936 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Mar |


Source: "World Population Prospects: The 2010 Revision", New York, United Nations and updates provided by Member States.
For tables 1-4, the monthly distribution of cases was based on date of rash onset. These monthly reported numbers may differ from reports produced by national or partner agencies if other dates (e.g. date of case reporting) are used.

## WHO EpiData

Monthly summary table 2: Reported rubella cases for the 12-month period Apr 2013 - Mar 2014 (data as of 29 April 2014)

| Country | Total Population ${ }^{1}$ | Incidence Rate <br> per <br> 1 million <br> population <br> Apr 13-Mar 14 | Total <br> rubella <br> cases <br> Apr 13- <br> Mar 14 | 2013-2014 (Year and month of rash onset) |  |  |  |  |  |  |  |  |  |  |  | Month of last report 2014 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Jan | Feb | Mar |  |
| Albania | 3238959 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Mar |
| Andorra | 67704 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | Feb |
| Armenia | 3116607 | 1.0 | 3 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Mar |
| Austria | 8432566 | 1.4 | 12 | 4 | 4 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | Mar |
| Azerbaijan | 9523077 | 0.1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | Mar |
| Belarus | 9503385 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Mar |
| Belgium* | 10801368 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | No Report |
| Bosnia and Herzegovina | 3736568 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | No Report |
| Bulgaria | 7350986 | 1.6 | 12 | 1 | 3 | 0 | 1 | 0 | 0 | 0 | 1 | - | 3 | 3 | 0 | Mar |
| Croatia | 4378643 | 0.2 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | Jan |
| Cyprus | 1140285 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | Feb |
| Czech Republic | 10573470 | 0.1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | - | 0 | 0 | 0 | Mar |
| Denmark* | 5607702 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Mar |
| Estonia | 1338490 | 1.5 | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Mar |
| Finland | 5413974 | 0.4 | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Mar |
| France* | 63742992 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | No Report |
| Georgia | 4278919 | 52.1 | 223 | 45 | 41 | 27 | 17 | 6 | 8 | 13 | 13 | 17 | 6 | 19 | 11 | Mar |
| Germany* | 81788064 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | No Report |
| Greece | 11441413 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | Mar |
| Hungary | 9932038 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Mar |
| Iceland | 331528 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | 0 | 0 | - | Feb |
| Ireland | 4628791 | 1.3 | 6 | 0 | 2 | 0 | 1 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | Mar |
| Israel | 7801150 | 0.1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | Mar |
| Italy | 60961372 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | No Report |
| Kazakhstan | 16552683 | 3.8 | 63 | 0 | 0 | 20 | 9 | 6 | 0 | 0 | 0 | 0 | 2 | 26 | - | Feb |
| Kyrgyzstan | 5515034 | 2.2 | 12 | 0 | 0 | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Mar |
| Latvia | 2225816 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Mar |
| Lithuania | 3280161 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Mar |
| Luxembourg | 528286 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | Mar |
| Malta | 420515 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Mar |
| Monaco | 38659 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | No Report |
| Montenegro | 633200 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | Feb |
| Netherlands | 16749476 | 3.4 | 57 | 2 | 0 | 12 | 43 | 0 | 0 | - | - | - | 0 | 0 | - | Feb |
| Norway | 4984475 | 0.8 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | Mar |
| Poland | 38317684 | 795.8 | 30493 | 10856 | 8466 | 4114 | 1877 | 690 | 569 | 606 | 481 | 485 | 769 | 669 | 911 | Mar |
| Portugal | 10694259 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | Mar |
| Republic of Moldova | 3504756 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Mar |
| Romania | 21343840 | 4.5 | 95 | 20 | 19 | 18 | 10 | 14 | 8 | 3 | 0 | 3 | 0 | 0 | 0 | Mar |
| Russian Federation | 142512768 | 1.1 | 160 | 22 | 16 | 10 | 5 | 7 | 2 | 2 | 6 | 67 | 9 | 8 | 6 | Mar |
| San Marino | 29625 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | No Report |
| Serbia | 9827512 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | No Report |
| Slovakia | 5486391 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Mar |
| Slovenia | 2043666 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Mar |
| Spain | 46949824 | 0.1 | 3 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Mar |
| Sweden | 9532211 | 0.1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | Mar |
| Switzerland | 7753209 | 0.8 | 6 | 3 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Mar |
| Tajikistan | 7190283 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Mar |
| The former Yugoslav Republic of Macedonia | 2068552 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Mar |
| Turkey | 75356656 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | No Report |
| Turkmenistan | 5232704 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | No Report |
| Ukraine | 44722880 | 0.2 | 9 | - | - | - | 9 | - | - | - | - | - | - | - | - | No Report |
| United Kingdom | 63162324 | 0.2 | 10 | 2 | 0 | 2 | 1 | 1 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | Mar |
| Uzbekistan | 28429936 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Mar |
| Total/Averages | 904217436 | 34.48 | 31177 | 10959 | 8555 | 4218 | 1977 | 725 | 587 | 627 | 504 | 574 | 793 | 727 | 929 |  |

[^1]*Belgium, Denmark, France and Germany do not have comprehensive rubella surveillance systems.

## WHO EpiData

Summary table 3: Classification, reporting and performance of measles, January - March 2014 (data as of 29 April 2014)

| Country | Total Population ${ }^{1}$ | Incidence per 1 million population (Apr 2013Mar 2014) | Total measles cases $^{2}$ | Classification |  |  |  |  | Reporting |  |  | Surveillance Indicators (Please click here to refer Annex 8 of MR Surveillance guideline) |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  | 응 른 0 0 0 |  |  |  |  |  |  |  |  |  |  |
| Albania | 3249478 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar | - | 0 | - |
| Andorra | 67664 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 67\% | 33\% | Feb | - | 0 | - |
| Armenia | 3125551 | 0 | 0 | 0 | 0 | 0 | 8 | 0 | 100\% | 100\% | Mar | 100\% | 0.26 | 100\% |
| Austria | 8448081 | 5.3 | 48 | 29 | 18 | 1 | 0 | 3 | 100\% | 100\% | Mar | 96.7\% | 0 | 95.8\% |
| Azerbaijan | 9633916 | 1.1 | 11 | 0 | 0 | 11 | 0 | 0 | 100\% | 100\% | Mar | 0.0\% | 0 | 36.4\% |
| Belarus | 9471470 | 0 | 0 | 0 | 0 | 0 | 54 | 0 | 100\% | 100\% | Mar | 98.1\% | 0.57 | 0 |
| Belgium | 10834237 | 1.3 | 14 | 3 | 3 | 8 | 8 | 0 | 100\% | 67\% | Mar | 52.6\% | 0.07 | 68.2\% |
| Bosnia and Herzegovina* | 3725925 | - | - | - | - | - | - | - | - | - | No Report | - | - | - |
| Bulgaria | 7301159 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar | - | 0 | - |
| Croatia | 4369385 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 100\% | 67\% | Mar | 100\% | 0 | 100\% |
| Cyprus | 1152528 | 3.5 | 4 | 2 | 2 | 0 | 0 | 0 | 100\% | 100\% | Mar | 100\% | 0 | 0 |
| Czech Republic | 10602464 | 6.2 | 68 | 68 | 0 | 0 | 0 | 2 | 100\% | 100\% | Mar | 100\% | 0 | 70.6\% |
| Denmark | 5626834 | 2.1 | 13 | 13 | 0 | 0 | 0 | 1 | 100\% | 100\% | Mar | 100\% | 0 | 100\% |
| Estonia | 1337486 | 0 | 0 | 0 | 0 | 0 | 8 | 0 | 100\% | 100\% | Mar | 100\% | 0.60 | 0 |
| Finland | 5431673 | 0.4 | 2 | 2 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar | 100\% | 0 | 0 |
| France | 64082436 | 1.5 | 106 | 49 | 28 | 29 | 0 | 10 | 67\% | 67\% | Mar | 80.8\% | 0 | 84.9\% |
| Georgia | 4251853 | 218.7 | 930 | 196 | 48 | 686 | 20 | 0 | 100\% | 0\% | Mar | 23.7\% | 0.47 | 97.6\% |
| Germany | 81628000 | 0.9 | 81 | 66 | 5 | 10 | 0 | 5 | 100\% | 100\% | Mar | 86.8\% | 0 | 100\% |
| Greece | 11465810 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar | - | 0 | - |
| Hungary | 9918162 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar | - | 0 | - |
| Iceland | 335344 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 67\% | 67\% | Feb | - | 0 | - |
| Ireland | 4679050 | 4.3 | 22 | 15 | 2 | 5 | 0 | 2 | 100\% | 100\% | Mar | 85.0\% | 0 | 50.0\% |
| Israel* | 7930896 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 100\% | 0\% | Mar | 100\% | 0 | 100\% |
| Italy | 61108864 | 12.1 | 791 | 294 | 288 | 209 | 18 | 53 | 100\% | 100\% | Mar | 59.3\% | 0.03 | 90.2\% |
| Kazakhstan* | 16708134 | 2.2 | 37 | 37 | 0 | 0 | 0 | 0 | 67\% | 67\% | Feb | 100\% | 0 | 0 |
| Kyrgyzstan | 5568088 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar | - | 0 | - |
| Latvia | 2217993 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar | - | 0 | - |
| Lithuania | 3265224 | 0.6 | 2 | 2 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar | 100\% | 0 | 100\% |
| Luxembourg | 535609 | 4.0 | 1 | 1 | - | - | - | - | - | - | No Report** | - | - | - |
| Malta | 421705 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar | - | 0 | - |
| Monaco | 39105 | - | - | - | - | - | - | - | - | - | No Report | - | - | - |
| Montenegro* | 633615 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 67\% | 67\% | Feb | - | 0 | - |
| Netherlands | 16802876 | 2.3 | 38 | 22 | 16 | 0 | 0 | 0 | 67\% | 67\% | Feb | 100\% | 0 | 100\% |
| Norway | 5018849 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar | - | 0 | - |
| Poland | 38331688 | 1.6 | 65 | 48 | 13 | 4 | 0 | 5 | 100\% | 100\% | Mar | 94.2\% | 0 | 100\% |
| Portugal | 10700137 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar | - | 0 | - |
| Republic of Moldova | 3477923 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar | - | 0 | - |
| Romania | 21291444 | 1.2 | 26 | 22 | 1 | 3 | 0 | 0 | 100\% | 100\% | Mar | 88.0\% | 0 | 100\% |
| Russian Federation | 142371600 | 18.2 | 2590 | 2262 | 0 | 328 | 13 | 0 | 100\% | 100\% | Mar | - | - | - |
| San Marino | 29750 | - | - | - | - | - | - | - | - | - | No Report | - | - | - |
| Serbia* | 9819308 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar | - | 0 | - |
| Slovakia | 5495762 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar | - | 0 | - |
| Slovenia | 2048169 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar | - | 0 | - |
| Spain | 47243756 | 0.2 | 13 | 10 | 2 | 1 | 9 | 3 | 100\% | 100\% | Mar | 100\% | 0.02 | 81.8\% |
| Sweden | 9589153 | 0.7 | 9 | 9 | 0 | 0 | 0 | 2 | 100\% | 100\% | Mar | 100\% | 0 | 100\% |
| Switzerland | 7783963 | 1.0 | 13 | 9 | 1 | 3 | 12 | 5 | 100\% | 67\% | Mar | 95.8\% | 0.15 | 56.0\% |
| Tajikistan* | 7294986 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar | - | 0 | - |
| The former Yugoslav Republic of Macedonia* | 2070647 | 22.2 | 46 | 37 | 0 | 9 | 0 | 0 | 100\% | 0\% | Mar | 80.4\% | 0 | 0 |
| Turkey | 76169160 | 4.5 | 340 | 337 | 3 | 0 | 0 | 0 | 100\% | 100\% | Mar | 100\% | 0 | 0 |
| Turkmenistan | 5300285 | - | - | - | - | - | - | - | - | - | No Report | - | - | - |
| Ukraine* | 44464092 | 22.0 | 977 | 312 | 0 | 665 | 0 | 0 | 100\% | 100\% | Mar | 31.9\% | 0 | 0 |
| United Kingdom | 63538392 | 1.0 | 86 | 86 | 0 | 0 | 0 | 22 | 100\% | 100\% | Mar | 100\% | 0 | 75.6\% |
| Uzbekistan* | 28739428 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar | - | 0 | - |
| Total/Averages | 906749107 | 6.9 | 6335 | 3933 | 430 | 1972 | 150 | 115 | 88.1\% | 79.9\% |  | 61.3\% | 0.02 | 39.7\% |

[^2][^3]${ }^{2}$ Imported and import-related measles cases are included in the total.
${ }^{3}$ Unless specified as lab confirmed or epi-linked, cases are classified as clinically compatible.

* Member States reporting aggregated measles data.
**No monthly case-based data reported. Cumulative aggregated number of cases for this period is hereby reported.
Indicators not meeting target and countries not reporting monthly measles data are highligted in red; "-" = data not submitted.


## WHO EpiData

Summary table 4: Classification, reporting and performance of rubella, January - March 2014 (data as of 29 April 2014)

| Country | Total Population ${ }^{1}$ | Incidence per 1 million population (Apr 2013Mar 2014) | Total rubella cases $^{2}$ | Classification |  |  |  |  | Reporting |  |  | Surveillance Indicators (Please click here to refer Annex 8 of MR Surveillance guideline) |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \\ & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & \text { y } \\ & \frac{1}{y} \\ & \cline { 1 - 1 } \end{aligned}$ |  |  |  |  |  |  |  |  |  |
| Albania | 3249478 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar | - | 0 | - |
| Andorra | 67664 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 67\% | 33\% | Feb | - | 0 | - |
| Armenia | 3125551 | 0 | 0 | 0 | 0 | 0 | 8 | 0 | 100\% | 0\% | Mar | 100\% | 0.26 | 100\% |
| Austria | 8448081 | 0.2 | 2 | 1 | 0 | 1 | 0 | 0 | 100\% | 100\% | Mar | 50.0\% | 0 | 100\% |
| Azerbaijan | 9633916 | 0.1 | 1 | 0 | 0 | 1 | 0 | 0 | 100\% | 100\% | Mar | 0 | 0 | 0 |
| Belarus | 9471470 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar | - | 0 | - |
| Belgium | 10834237 | - | - | - | - | - | - | - | - | - | No Report | - | - | - |
| Bosnia and Herzegovina | 3725925 | - | - | - | - | - | - | - | - | - | No Report | - | - | - |
| Bulgaria | 7301159 | 0.8 | 6 | 1 | 0 | 5 | 0 | 0 | 67\% | 67\% | Mar | 0 | 0 | 83.3\% |
| Croatia | 4369385 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 33\% | 33\% | Jan | - | 0 | - |
| Cyprus | 1152528 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 67\% | 67\% | Feb | - | 0 | - |
| Czech Republic | 10602464 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar | - | 0 | - |
| Denmark | 5626834 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar | - | 0 | - |
| Estonia | 1337486 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 100\% | 100\% | Mar | 100\% | 0.15 | 100\% |
| Finland | 5431673 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar | - | 0 | - |
| France | 64082436 | - | - | - | - | - | - | - | - | - | No Report | - | - | - |
| Georgia | 4251853 | 8.5 | 36 | 1 | 0 | 35 | 10 | 0 | 100\% | 0\% | Mar | 21.7\% | 0.24 | 100\% |
| Germany | 81628000 | - | - | - | - | - | - | - | - | - | No Report | - | - | - |
| Greece | 11465810 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar | - | 0 | - |
| Hungary | 9918162 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar | - | 0 | - |
| Iceland | 335344 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 67\% | 67\% | Feb | - | 0 | - |
| Ireland | 4679050 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar | - | 0 | - |
| Israel | 7930896 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar | - | 0 | - |
| Italy | 61108864 | - | - | - | - | - | - | - | - | - | No Report | - | - | - |
| Kazakhstan | 16708134 | 1.7 | 28 | 6 | 0 | 22 | 0 | 0 | 67\% | 67\% | Feb | 0 | 0 | 0 |
| Kyrgyzstan | 5568088 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar | - | 0 | - |
| Latvia | 2217993 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar | - | 0 | - |
| Lithuania | 3265224 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar | - | 0 | - |
| Luxembourg | 535609 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 67\% | 67\% | Mar | - | 0 | - |
| Malta | 421705 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar | - | 0 | - |
| Monaco | 39105 | - | - | - | - | - | - | - | - | - | No Report | - | - | - |
| Montenegro | 633615 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 67\% | 67\% | Feb | - | 0 | - |
| Netherlands | 16802876 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 67\% | 67\% | Feb | - | 0 | - |
| Norway | 5018849 | 0 | 3 | 2 | 1 | 0 | 0 | 3 | 100\% | 100\% | Mar | 100\% | 0 | 100\% |
| Poland | 38331688 | 61.3 | 2349 | 0 | 0 | 2349 | 0 | 0 | 100\% | 100\% | Mar | 0 | 0 | 0 |
| Portugal | 10700137 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar | - | 0 | - |
| Republic of Moldova | 3477923 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar | - | 0 | - |
| Romania | 21291444 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar | - | 0 | - |
| Russian Federation | 142371600 | 0.2 | 23 | 23 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar | 0 | 0 | 0 |
| San Marino | 29750 | - | - | - | - | - | - | - | - | - | No Report | - | - | - |
| Serbia | 9819308 | - | - | - | - | - | - | - | - | - | No Report | - | - | - |
| Slovakia | 5495762 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar | - | 0 | - |
| Slovenia | 2048169 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar | - | 0 | - |
| Spain | 47243756 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar | - | 0 | - |
| Sweden | 9589153 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 100\% | 100\% | Mar | 100\% | 0 | 100\% |
| Switzerland | 7783963 | 0 | 0 | 0 | 0 | 0 | 11 | 0 | 100\% | 0\% | Mar | 90.9\% | 0.14 | 9.1\% |
| Tajikistan | 7294986 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 100\% | 100\% | Mar | 100\% | 0.01 | 100\% |
| The former Yugoslav Republic of Macedonia | 2070647 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100\% | 0\% | Mar | - | 0 | - |
| Turkey | 76169160 | - | - | - | - | - | - | - | - | - | No Report | - | - | - |
| Turkmenistan | 5300285 | - | - | - | - | - | - | - | - | - | No Report | - | - | - |
| Ukraine | 44464092 | - | - | - | - | - | - | - | - | - | No Report | - | - | - |
| United Kingdom | 63538392 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar | - | 0 | - |
| Uzbekistan | 28739428 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar | - | 0 | - |
| Total/Averages | 906749107 | 2.7 | 2449 | 35 | 1 | 2413 | 32 | 4 | 73.0\% | 64.8\% |  | 1.5\% | 0 | 2.8\% |

[^4]${ }^{1}$ Source: "World Population Prospects: The 2010 Revision", New York, United Nations and updates provided by Member States.
${ }^{2}$ Imported and import-related measles cases are included in the total.
${ }^{3}$ Unless specified as lab confirmed or epi-linked, cases are classified as clinically compatible.
Indicators not meeting target and countries not reporting monthly rubella data are highligted in red. "-" indicates data not submitted.

Summary table 5: Measles and rubella laboratory test results, January - March 2014 (data as of 29 April 2014)

|  | Specimen* (Serum, Oral Fluid, Swab, Urine and other) |  |  |  |  |  |  |  | Reporting |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Country | Tested for measles | Positive for measles (\%) | Measles <br> Equivocal | Negative for measles | Tested for rubella | Positive for rubella (\%) | Rubella <br> Equivocal | Negative <br> for rubella | \% Complete ness |  | Month of last report |
| Albania | 3 | 0 (0.0) | 0 | 3 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar |
| Andorra |  |  |  |  |  |  |  |  |  |  | No Lab |
| Armenia | 18 | 0 (0.0) | 0 | 18 | 18 | 0 (0.0) | 0 | 18 | 100\% | 100\% | Mar |
| Austria | 397 | 34 (9.0) | 0 | 363 | 1436 | 0 (0.0) | 0 | 1436 | 100\% | 100\% | Mar |
| Azerbaijan | - |  | - | - | - |  | - | - | - | - | No Report |
| Belarus | 58 | 0 (0.0) | 0 | 58 | 58 | 0 (0.0) | 0 | 58 | 100\% | 100\% | Mar |
| Belgium | 32 | 4 (13.0) | 1 | 27 | 33 | 6 (18.0) | 4 | 23 | 100\% | 33.3\% | Mar |
| Bosnia and Herzegovina | - |  | - | - | - |  | - | - | - | - | No Report |
| Bulgaria | 9 | 0 (0.0) | 0 | 9 | 12 | 0 (0.0) | 0 | 12 | 100\% | 100\% | Mar |
| Croatia | 3 | 3 (100.0) | 0 | 0 | 1 | 0 (0.0) | 0 | 1 | 100\% | 100\% | Mar |
| Cyprus | 33 | 2 (6.0) | 0 | 31 | 108 | 0 (0.0) | 0 | 108 | 100\% | 66.7\% | Mar |
| Czech Republic | 124 | 44 (35.0) | 23 | 57 | 2 | 1 (50.0) | 0 | 1 | 100\% | 100\% | Mar |
| Denmark | 244 | 21 (9.0) | 1 | 222 | 42 | 0 (0.0) | 1 | 41 | 100\% | 100\% | Mar |
| Estonia | 133 | 0 (0.0) | 0 | 133 | 239 | 4 (2.0) | 0 | 235 | 100\% | 100\% | Mar |
| Finland | 118 | 4 (3.0) | 0 | 114 | 185 | 0 (0.0) | 0 | 185 | 100\% | 100\% | Mar |
| France | 169 | 29 (17.0) | 5 | 135 | 81 | 0 (0.0) | 0 | 81 | 100\% | 66.7\% | Mar |
| Georgia | - |  | - | 0 | 0 |  | - | - | - | - | No Report |
| Germany | 67 | 19 (28.0) | 0 | 48 | 20 | 1 (5.0) | 0 | 19 | 100\% | 100\% | Mar |
| Greece | - |  | - | - | - |  | - | - | - | - | No Report |
| Hungary | 15 | 0 (0.0) | 0 | 15 | 62 | 0 (0.0) | 0 | 62 | 100\% | 100\% | Mar |
| Iceland | - |  | - | - | - |  | - | - | - | - | No Report |
| Ireland | 148 | 25 (17.0) | 2 | 121 | 422 | 3 (1.0) | 0 | 419 | 100\% | 100\% | Mar |
| Israel | 44 | 10 (23.0) | 0 | 34 | 186 | 38 (20.0) | 0 | 148 | 100\% | 100\% | Mar |
| Italy | - |  | - | - | - |  | - | - | - | - | No Report |
| Kazakhstan | 141 | 75 (53.0) | 0 | 66 | 103 | 6 (6.0) | 0 | 97 | 100\% | 100\% | Mar |
| Kyrgyzstan | 29 | 0 (0.0) | 1 | 28 | 29 | 0 (0.0) | 1 | 28 | 66.7\% | 66.7\% | Feb |
| Latvia | 63 | 14 (22.0) | 0 | 49 | 67 | 1 (1.0) | 1 | 65 | 100\% | 66.7\% | Mar |
| Lithuania | 10 | 2 (20.0) | 2 | 6 | 8 | 0 (0.0) | 0 | 7 | 100\% | 100\% | Mar |
| Luxembourg | 32 | 2 (6.0) | 1 | 29 | 9 | 0 (0.0) | 0 | 9 | 100\% | 100\% | Mar |
| Malta | 10 | 0 (0.0) | 0 | 10 | 387 | 1 (0.0) | 0 | 386 | 100\% | 33.3\% | Mar |
| Monaco |  |  |  |  |  |  |  |  |  |  | No Lab |
| Montenegro |  |  |  |  |  |  |  |  |  |  | No Lab |
| Netherlands | 86 | 52 (60.0) | 0 | 34 | 86 | 0 (0.0) | 0 | 86 | 100\% | 33.3\% | Mar |
| Norway | 8 | 0 (0.0) | 0 | 8 | 27 | 2 (7.0) | 0 | 25 | 100\% | 100\% | Mar |
| Poland | 208 | 121 (58.0) | 2 | 85 | 41 | 8 (20.0) | 1 | 32 | 100\% | 100\% | Mar |
| Portugal | 3 | 0 (0.0) | 0 | 3 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar |
| Republic of Moldova | 4 | 0 (0.0) | 0 | 4 | 4 | 0 (0.0) | 0 | 4 | 100\% | 100\% | Mar |
| Romania | 86 | 13 (15.0) | 0 | 73 | 89 | 8 (9.0) | 0 | 81 | 100\% | 100\% | Mar |
| Russian Federation | 3947 | 2443 (62.0) | 10 | 1494 | 1721 | 42 (2.0) | 6 | 1671 | 100\% | 100\% | Mar |
| San Marino |  |  |  |  |  |  |  |  |  |  | No Lab |
| Serbia | 9 | 0 (0.0) | 0 | 9 | 54 | 0 (0.0) | 0 | 54 | 100\% | 100\% | Mar |
| Slovakia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100\% | 100\% | Mar |
| Slovenia | 11 | 0 (0.0) | 0 | 11 | 10 | 0 (0.0) | 0 | 10 | 100\% | 100\% | Mar |
| Spain | - |  | - | - | - |  | - | - | - | - | No Report |
| Sweden | - |  | - | - | - |  | - | - | - | - | No Report |
| Switzerland | 32 | 17 (53.0) | 1 | 13 | 6 | 6 (100.0) | 0 | 0 | 100\% | 100\% | Mar |
| Tajikistan | - |  | - | - | - |  | - | - | - | - | No Report |
| The former Yugoslav Republic of Macedonia | - | 35 (56.0) | - | - | - | 0 (0.0) | - | - | - | - | Mar |
| Turkey | 0 |  | 0 | 0 | 0 |  | 0 | 0 | 0 | 0 | No Report |
| Turkmenistan | 0 |  | 0 | 0 | 0 |  | 0 | 0 | 0 | 0 | No Report |
| Ukraine | 257 | 124 (48.0) | 1 | 120 | 148 | 37 (25.0) | 0 | 111 | 100\% | 100\% | Mar |
| United Kingdom | 1220 | 130 (11.0) | 0 | 1090 | 268 | 1 (0.0) | 0 | 267 | 100\% | 66.7\% | Mar |
| Uzbekistan | 7 | 0 (0.0) | 0 | 7 | 7 | 0 (0.0) | 0 | 7 | 100\% | 100\% | Mar |
| Total / Average | 7778 | 3223 (41\%) | 50 | 4527 | 5969 | 165 (3\%) | 14 | 5787 | 77.9\% | 71.0\% |  |

Data source: Aggregated monthly data provided by regional measles and rubella laboratory network (MR Labnet) to WHO/Europe.
*Specimen based data are not population based, and should not be interpreted as indicators for epidemiological surveillance. Laboratories may have received more than 1 clinical sample or may have conducted more than 1 test for a given case reported in Table 1.

Summary table 6: Classification of AFP cases, surveillance performance and weekly reporting by country to WHO European Regional office, 2013-2014

| Countries | 2013(1-52 weeks) |  |  |  |  |  |  |  |  |  |  | 2014 (1-16 weeks) |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  | Classification |  |  |  |  | Rates |  |  | $\begin{aligned} & \text { "\$ } \\ & 0 \\ & 0 \\ & \hline 0 \\ & \frac{1}{4} \end{aligned}$ |  |  | Classification |  |  |  |  | Rates |  |  | Reporting |  |  |
|  |  |  |  | $\begin{aligned} & \text { 응 } \\ & \text { 응 } \\ & \text { 흘 } \\ & \frac{1}{3} \end{aligned}$ | $\begin{aligned} & \text { 이 } \\ & \text { \%i } \\ & 0 . \\ & 0 \\ & 0 . \end{aligned}$ | $\frac{0}{2}$ <br> $\frac{0}{4}$ <br> 3 <br> 0 <br> 0 |  | $\begin{aligned} & \text { 응 } \\ & \frac{5}{\circ} \\ & \text { 웅 } \end{aligned}$ | $\begin{aligned} & \text { Non polio AFP } \\ & \text { rate }^{3} \end{aligned}$ |  |  |  |  |  | Wild Polio cases | $\begin{aligned} & \text { ర్ } \\ & \text { O} \\ & \frac{0}{0} \\ & 0 \\ & 0 \end{aligned}$ | $\frac{0}{n}$ $\frac{n}{n}$ 3 0 0 $>$ |  | 응 <br> 응 | 은 응 "응 들 |  |  | 9 <br> 0 <br> 0 <br> 9 <br> 0 <br> 0 <br> 0 <br>  <br> 0 <br> 0 <br> 0 |  |  |
| Albania | 6 | 6 | 0 | 0 | 6 | 0 | 0 | 0 | 0.88 | 83.3 | 0.74 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0.00 | 100.0 | 0.00 | 87.50 | 81.25 | 16 |
| Andorra | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 | 0.0 | 0.00 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 | 0.0 | 0.00 | 62.50 | 6.25 | 10 |
| Armenia | 22 | 22 | 1 | 0 | 22 | 0 | 0 | 0 | 3.44 | 100.0 | 1.00 | 4 | 4 | 0 | 0 | 2 | 0 | 0 | 2 | 0.94 | 100.0 | 0.94 | 100.00 | 100.00 | 17 |
| Austria | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 4 | 0.00 | 0.0 | 0.00 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0.00 | 0.0 | 0.00 | 93.75 | 75.00 | 15 |
| Azerbaijan | 20 | 20 | 0 | 0 | 20 | 0 | 0 | 0 | 0.96 | 95.0 | 0.91 | 5 | 5 | 0 | 0 | 0 | 0 | 0 | 5 | 0.00 | 100.0 | 0.00 | 93.75 | 93.75 | 16 |
| Belarus | 42 | 42 | 3 | 0 | 42 | 0 | 0 | 0 | 2.87 | 92.9 | 0.93 | 14 | 14 | 0 | 0 | 0 | 0 | 0 | 14 | 0.00 | 85.7 | 0.00 | 56.25 | 56.25 | 13 |
| Belgium | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 | 0.0 | 0.00 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 | 0.0 | 0.00 | 100.00 | 62.50 | 16 |
| *Bosnia and Herzegovina | 8 | 8 | 0 | 0 | 8 | 0 | 0 | 0 | 1.53 | 87.5 | 0.67 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0.00 | 100.0 | 0.00 | 87.50 | 81.25 | 16 |
| Bulgaria | 13 | 13 | 0 | 0 | 13 | 0 | 0 | 0 | 1.24 | 84.6 | 0.85 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 3 | 0.00 | 100.0 | 0.00 | 6.25 | 6.25 | 6 |
| Croatia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 | 0.0 | 0.00 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 | 0.0 | 0.00 | 100.00 | 50.00 | 17 |
| Cyprus | 3 | 3 | 0 | 0 | 2 | 0 | 0 | 1 | 1.03 | 100.0 | 1.00 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0.00 | 100.0 | 0.00 | 100.00 | 100.00 | 17 |
| Czech Republic | 10 | 10 | 0 | 0 | 10 | 0 | 0 | 0 | 0.65 | 80.0 | 0.52 | 2 | 2 | 0 | 0 | 2 | 0 | 0 | 0 | 0.39 | 100.0 | 0.39 | 100.00 | 100.00 | 16 |
| Estonia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 | 0.0 | 0.00 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 | 0.0 | 0.00 | 100.00 | 100.00 | 17 |
| *Georgia | 10 | 10 | 0 | 0 | 10 | 0 | 0 | 0 | 1.41 | 100.0 | 0.70 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 2 | 0.00 | 100.0 | 0.00 | 87.50 | 87.50 | 16 |
| Greece | 23 | 23 | 1 | 0 | 23 | 0 | 0 | 0 | 1.36 | 91.3 | 0.62 | 8 | 8 | 0 | 0 | 0 | 0 | 0 | 8 | 0.00 | 100.0 | 0.00 | 100.00 | 87.50 | 16 |
| Hungary | 16 | 16 | 0 | 0 | 16 | 0 | 0 | 0 | 1.09 | 62.5 | 0.63 | 5 | 5 | 0 | 0 | 1 | 0 | 0 | 4 | 0.21 | 40.0 | 0.08 | 100.00 | 100.00 | 17 |
| Israel | 61 | 32 | 3 | 0 | 61 | 0 | 0 | 0 | 2.86 | 50.0 | 0.56 | 7 | 7 | 1 | 0 | 7 | 0 | 0 | 0 | 0.99 | 100.0 | 0.99 | 100.00 | 68.75 | 17 |
| Italy | 66 | 66 | 0 | 0 | 66 | 0 | 0 | 0 | 0.77 | 62.1 | 0.52 | 12 | 12 | 0 | 0 | 3 | 0 | 0 | 9 | 0.11 | 75.0 | 0.09 | 93.75 | 81.25 | 15 |
| Kazakhstan | 101 | 99 | 1 | 0 | 99 | 0 | 0 | 2 | 2.33 | 100.0 | 1.00 | 21 | 21 | 0 | 0 | 9 | 0 | 0 | 12 | 0.63 | 100.0 | 0.63 | 100.00 | 100.00 | 16 |
| Kyrgyzstan | 77 | 72 | 1 | 0 | 63 | 0 | 0 | 14 | 3.84 | 94.4 | 0.96 | 6 | 5 | 0 | 0 | 2 | 0 | 0 | 4 | 0.37 | 60.0 | 0.22 | 68.75 | 68.75 | 16 |
| Latvia | 2 | 2 | 0 | 0 | 2 | 0 | 0 | 0 | 0.62 | 100.0 | 0.62 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 | 0.0 | 0.00 | 100.00 | 68.75 | 16 |
| Lithuania | 12 | 11 | 0 | 0 | 12 | 0 | 0 | 0 | 2.48 | 100.0 | 1.00 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 | 0.0 | 0.00 | 100.00 | 93.75 | 16 |
| Malta | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 | 0.0 | 0.00 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 3 | 0.00 | 0.0 | 0.00 | 12.50 | 12.50 | 15 |
| Montenegro | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 | 0.0 | 0.00 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 | 0.0 | 0.00 | 100.00 | 100.00 | 16 |
| Norway | 8 | 7 | 1 | 0 | 7 | 0 | 0 | 1 | 0.76 | 14.3 | 0.11 | 3 | 2 | 0 | 0 | 1 | 0 | 0 | 2 | 0.33 | 100.0 | 0.33 | 62.50 | 56.25 | 15 |
| Poland | 41 | 41 | 0 | 0 | 39 | 1 | 0 | 1 | 0.69 | 68.3 | 0.52 | 14 | 14 | 0 | 0 | 1 | 0 | 0 | 13 | 0.05 | 85.7 | 0.05 | 100.00 | 93.75 | 17 |
| Portugal | 5 | 5 | 0 | 0 | 5 | 0 | 0 | 0 | 0.32 | 60.0 | 0.19 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0.00 | 100.0 | 0.00 | 18.75 | 18.75 | 4 |
| Republic of Moldova | 3 | 3 | 0 | 0 | 3 | 0 | 0 | 0 | 0.52 | 66.7 | 0.34 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 | 0.0 | 0.00 | 100.00 | 100.00 | 17 |
| *Romania | 22 | 22 | 0 | 0 | 22 | 0 | 0 | 0 | 0.68 | 100.0 | 0.34 | 9 | 9 | 0 | 0 | 3 | 0 | 0 | 6 | 0.28 | 100.0 | 0.14 | 62.50 | 56.25 | 17 |
| Russian Federation | 368 | 366 | 62 | 0 | 362 | 6 | 0 | 0 | 1.60 | 94.8 | 0.96 | 103 | 102 | 18 | 0 | 22 | 0 | 0 | 81 | 0.29 | 96.1 | 0.28 | 100.00 | 100.00 | 18 |
| Serbia | 15 | 15 | 1 | 0 | 15 | 0 | 0 | 0 | 0.88 | 86.7 | 0.76 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0.00 | 0.0 | 0.00 | 87.50 | 87.50 | 16 |
| Slovakia | 2 | 2 | 0 | 0 | 2 | 0 | 0 | 0 | 0.24 | 50.0 | 0.12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 | 0.0 | 0.00 | 100.00 | 81.25 | 16 |
| Slovenia | 2 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0.69 | 0.0 | 0.00 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 | 0.0 | 0.00 | 87.50 | 87.50 | 16 |
| Spain | 26 | 26 | 0 | 0 | 26 | 0 | 0 | 0 | 0.36 | 57.7 | 0.21 | 18 | 18 | 1 | 0 | 11 | 0 | 0 | 7 | 0.46 | 50.0 | 0.28 | 100.00 | 87.50 | 16 |
| Switzerland | 8 | 8 | 0 | 0 | 8 | 0 | 0 | 0 | 0.69 | 12.5 | 0.09 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0.27 | 0.0 | 0.27 | 93.75 | 37.50 | 15 |
| Tajikistan | 83 | 83 | 0 | 0 | 78 | 0 | 0 | 5 | 3.03 | 89.2 | 0.89 | 13 | 13 | 0 | 0 | 2 | 0 | 0 | 11 | 0.24 | 100.0 | 0.24 | 68.75 | 68.75 | 15 |
| The former Yugoslav Republic of Macedonia | 4 | 4 | 0 | 0 | 4 | 0 | 0 | 0 | 1.16 | 100.0 | 1.00 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0.00 | 100.0 | 0.00 | 100.00 | 100.00 | 16 |
| Turkey | 231 | 230 | 10 | 0 | 231 | 0 | 0 | 0 | 1.22 | 75.7 | 0.80 | 77 | 76 | 3 | 0 | 46 | 0 | 0 | 31 | 0.74 | 84.2 | 0.64 | 100.00 | 100.00 | 16 |
| Turkmenistan | 33 | 33 | 0 | 0 | 20 | 2 | 0 | 11 | 1.35 | 97.0 | 1.00 | 7 | 7 | 0 | 0 | 0 | 0 | 0 | 7 | 0.00 | 100.0 | 0.00 | 62.50 | 62.50 | 16 |
| *Ukraine | 129 | 129 | 23 | 0 | 127 | 0 | 0 | 2 | 1.92 | 100.0 | 0.96 | 40 | 39 | 5 | 0 | 0 | 0 | 0 | 40 | 0.00 | 92.3 | 0.00 | 93.75 | 93.75 | 16 |
| Uzbekistan | 197 | 195 | 0 | 0 | 197 | 0 | 0 | 0 | 2.47 | 96.4 | 0.96 | 37 | 34 | 0 | 0 | 20 | 0 | 0 | 17 | 0.77 | 100.0 | 0.77 | 68.75 | 68.75 | 16 |
| Average/Total | 1673 | 1629 | 107 | 0 | 1623 | 9 | 0 | 41 | 1.25 | 87.00 |  | 422 | 411 | 29 | 0 | 133 | 0 | 0 | 289 | 0.44 | 88.00 | 0.39 | 84.3 | 75.2 |  |

${ }^{1}$ AFP cases of all ages (Denmark, Germany, Finland, France, Ireland, Iceland, Luxembourg, Monaco, Netherlands, San Marino, Sweden and United Kingdom do not report AFP cases).
${ }^{2}$ Hot cases = AFP case reported with a priority code (e.g. less than three doses of polio vaccine/Clinically polio/Recent travel to endemic country/high risk group).
${ }^{3}$ Non-polio AFP cases per 100000 children under the age of 15 years (annualized for current year). Number of non-polio (discarded) AFP cases X 100000 / total population under 15 years.
${ }^{4}$ two stool specimens collected $24-48$ hours apart within 14 days of the onset of paralysis
Surveilance Index = non-polio AFP rate up to $1.0 \times$ (\% AFP cases with atleast two adequate specimens within 14 days of onset).
 specimens within 14 days of onset)

Contact us: Vaccine-preventable Diseases and Immunization Programme , WHO Regional Office for Europe
Tel.: +4545337000 E-mail: vaccine@euro.who.int
Web site: http://www.euro.who.int © World Health Organization, 2014.


[^0]:    ${ }^{1}$ World Health Organization. Centralized Information system for infectious diseases (CISID) http://data.euro.who.int/CISID/
    ${ }^{2}$ WHO EpiData no. 3/2014, attached to this report and available at http://www.euro.who.int/__data/assets/pdf_file/0006/249243/EpiData3-2014.pdf?ua=1
    ${ }^{3}$ Measles Nucleotide Surveillance database (MeaNs) www.who-measles.org/

[^1]:    ${ }^{1}$ Source: "World Population Prospects: The 2010 Revision", New York, United Nations and updates provided by Member States.

[^2]:    Data source : Monthly aggregated and case-based data reported by Member States to WHO/Europe and ECDC/TESSy

[^3]:    ${ }^{1}$ Source: "World Population Prospects: The 2010 Revision", New York, United Nations and updates provided by Member States.

[^4]:    Data source : Monthly agsregated and case-based data reported by Member States to WHOFurope and ECDC/

